Valiltramiprosate is under clinical development by Alzheon and currently in Phase II for Unspecified Central Nervous System Disorders. According to GlobalData, Phase II drugs for Unspecified Central Nervous System Disorders have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Valiltramiprosate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Valiltramiprosate overview
ALZ-801 is under development for the treatment of Alzheimer’s disease, cerebral amyloid angiopathy (CAA) and Down syndrome. The drug candidate is a prodrug of tramiprosate. It is a small molecule formulated as a pill and administered orally. It acts by targeting beta-amyloid protein 42 (amyloid precursor protein). The drug candidate was also under development for the treatment of cerebral amyloid angiopathy, familial AD (Alzheimer’s disease) and traumatic brain injury, inclusion body myositis and age-related macular degeneration.
Alzheon overview
Alzheon is a clinical-stage biopharmaceutical company that discovers platform of small molecules for the treatment of neurodegenerative disorders. It develops disease modifying treatments by leveraging in inhibiting protein misfolding and aggregation. The company’s pipeline products include ALZ-801 (valiltramiprosate) which is oral anti-amyloid treatment for Alzheimer’s disease; ALZ-1903 for dry age-related macular degeneration (AMD), body myositis and amyloid-related disorders. It uses discovery platform designed to inhibit the misfolding of proteins associated with neurodegenerative diseases. Alzheon is headquartered in Framingham, Massachusetts, the US.
For a complete picture of Valiltramiprosate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
